vimarsana.com
Home
Live Updates
Inhalon Doses First Patient in Phase 1 Study of Inhaled IN-0
Inhalon Doses First Patient in Phase 1 Study of Inhaled IN-0
Inhalon Doses First Patient in Phase 1 Study of Inhaled IN-006 to Treat COVID-19
/PRNewswire/ -- Inhalon Biopharma, Inc., a clinical-stage immunotherapy company developing an inhaled "muco-trapping" antibody platform for treating acute...
Related Keywords
United Kingdom ,
Berkeley ,
California ,
United States ,
Jason Lickliter ,
John Whelan ,
Johnb Whelan ,
Sam Lai ,
Inhalon Biopharma ,
Edie Devine ,
Johns Hopkins University ,
Inhalon Biopharma Inc ,
Us Army Medical Research Development Command ,
Company Contact ,
University Of North Carolina ,
Celltrion Inc ,
Nucleus Network Inc ,
Thiel Foundation Breakout Labs ,
Berkeley Catalyst Fund ,
Emergency Use Authorization ,
Chief Medical Officer ,
Nucleus Network ,
Medical Research ,
Development Command ,
North Carolina ,
Chapel Hill ,
Johns Hopkins ,
Thiel Foundation ,
Breakout Labs ,
Life Science Angels ,
Sand Hill Angels ,